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risk of cardiovascular morbidity and mortality due to
underlying coronary artery disease.1 It is estimated that
the incidence of perioperative myocardial infarction (MI) is
up to 5e10% in unselected patient populations.2 However,
in the perioperative setting, it is difficult to rely on
patients’ symptoms for the detection of cardiac events as
symptoms might very well be atypical or absent due to
residual anaesthetic effects, administration of analgesic
agents and competing somatic stimuli such as incisional
pain.3
Postoperative cardiac screening of vascular surgery
patients using cardiac troponin T (cTnT) and continuous
12-lead electrocardiography (ECG) monitoring might help
to timely identify asymptomatic patients experiencing
a postoperative cardiac event. While ECG changes are
often transient and continuous, ECG monitoring is time
consuming, cardiac troponins are biomarkers highly
sensitive for the detection of a perioperative MI.
Furthermore, the half-life of cardiac troponins is 6 h,
which increases the chance of detection. Importantly,
recent studies using highly sensitive troponin assays have
demonstrated that low-level troponin elevations
(>0.03 ng ml1) are common in high cardiac risk patients
postoperatively, often with no evidence of ECG changes of
ischaemia.4 CTnT assays detect low levels of troponin;
however, the detection level has significantly improved,
indicating that more patients with troponin release are
identified. The clinical implications of these measure-
ments are lacking; therefore, a quantitative measurement
of cTnT was studied.
However, besides the strong association between
cardiac risk and perioperative ischaemia characterised by
cTnT release, and its influence on short- and long-term
outcome, little is known regarding the measurement of
this serum marker within the first 30 days, post-
operatively. Therefore, the present study was conducted
to establish the additional prognostic and possible thera-
peutic consequences of cTnT area under the curve
(cTnTeAUC) in patients undergoing elective vascular
surgery.Methods
Study population
The study population consisted of 513 unique patients
undergoing vascular surgery at the Erasmus Medical Center
in Rotterdam, The Netherlands, during the period from
December 2004 to November 2009. Patients with a history
of cardiac arrhythmias, cardiac pacemaker, preoperative
cTnT release and procedures that precluded continuous
ECG monitoring were excluded. The hospital’s ethical
committee approved the study.Preoperative risk assessment
We determined the cardiac risk score for each patient in our
dataset, and one point was assigned to each of the following
characteristics:2 advanced age (>70 years), history of MI,
angina pectoris (AP), congestive heart failure (CHF), stroke
(transient ischaemic attack and/or cerebral vascular
accident), diabetes mellitus (fasting glucose level
7.0 mmol l1 or use of insulin or oral glucose-lowering
medication) and renal insufficiency (serum creatinine
>170 mmol l1). Based on the number of these risk factors,
patients were stratified into low risk (no risk factors),
intermediate risk (one or two risk factors) and high risk
(three risk factors) categories.2 All patients were
screened for hypertension (blood pressure 140/
90 mmHg or blood pressure-lowering medication), hyper-
cholesterolaemia (plasma cholesterol level 5.5 mmol l1
or use of cholesterol-lowering medication), smoking status
and chronic obstructive pulmonary disease (COPD).5 In all
patients, beta-blockers were prescribed prior to surgery to
obtain perioperative heart rates of 60e70 beats min1.6
After the visit to the outpatient clinic, patients were
prescribed with beta-blockers, statins, anti-platelet and/or
anticoagulant medication.
ECG monitoring
Patients were continuously monitored with a 10-electrode,
12-lead digital ECG recorder (DR180 þ Digital Recorder,
NorthEast Monitoring Inc., Maynard, MA, USA) for 72 h
perioperatively, initiated 1 day before and continued until
48 h after the surgical procedure. Recordings were per-
formed in the continuous 12-lead mode with a recording
cycle of 10 s every minute. Signal bandwidth ranged from
0.05 Hz to 150 Hz. Electrocardiographic data were initially
processed by a technician to exclude artefacts, and then
analysed for the presence of myocardial ischaemia. Stan-
dard postoperative 12-lead ECGs were made on days 3, 7
and 30, and/or at discharge and whenever clinically indi-
cated. Using 12-lead ECG, patients with a perioperative
MI were categorised into acute ST-segment elevation MI
(STEMI; defined by the presence of ST-segment elevation
0.1 mV in unipolar leads and confirmed by elevated cTnT
above 0.03 ng ml1)7,8 and non-ST-segment elevation MI
(non-STEMI; defined by an elevation of cTnT above
0.03 ng ml1, on at least one occasion within 24 h after the
ischaemic index event, with a rise or fall during subsequent
sampling).7,8
Episodes of ischaemia on continuous ECG were defined
as reversible ST-segment changes, lasting at least 1 min and
shifting from baseline by more than 0.1 mV (1 mm).
ST-segment amplitude was measured 60 ms after the J
point. If the J point fell within the T-wave, the ST-segment
change was measured 40 ms after that point.9 The baseline
ST-segment level was defined as the average ST-segment
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The criteria for an ST-depression and ST-elevation were
0.1 mV flat or downsloping morphology with deviated
J point.10
CTnT measurement
After surgery, cTnT levels were routinely measured on
postoperative days 1, 3, 7, 30 and/or before discharge and/
or whenever clinically indicated by chest pain complaints
or ECG changes consistent with myocardial ischaemia or
infarction. On average, there were five cTnT measure-
ments per patient. The cTnT level was measured using
a whole-blood rapid test by an electrochemiluminescence
immunoassay (TropT version 2, Roche Diagnostics GmbH,
Mannheim, Germany). The lower limit of cTnT detection
was 0.01 ng ml1 and the upper limit of detection was
25 ng ml1, with the limit of quantification set at
0.03 ng ml1. If cTnT release occurred, measurements were
repeated every day until the level returned to baseline
value. Absolute cTnT levels were noted, peak value of cTnT
was measured and the release pattern was presented as
AUC (days*ng ml1).
Long-term outcome
During follow-up, outpatient visits were scheduled every 3
months after discharge. Survival status was determined by
contacting the municipal civil service registry. The
endpoints of the study were all-cause mortality and
adverse cardiovascular events (cardiovascular death, non-
fatal MI and unstable angina) during long-term follow-up
(2.0 years; interquartile range (IQR) 1.1e3.1 years). MI was
defined as the presence of two out of the following three
criteria: (1) typical chest pain complaints, (2) electrocar-
diographic changes including acute ST-elevation, followed
by appearance of Q waves or loss of R waves, or new left
bundle branch block, or new persistent T-wave inversion
for at least 24 h or new ST-segment depression which
persists >24 h and (3) a positive troponin T, that is,
>0.10 ng ml1 with characteristic rise and fall.8 Cardio-
vascular death was defined as any death with a cardiovas-
cular cause, including deaths following a cardiac
procedure, cardiac arrest, MI, pulmonary embolus, stroke
or sudden death not ascribed to other causes.11 No patients
were lost to follow-up.
Data analysis
Continuous data are expressed as means  standard devi-
ation (SD) compared using the Student’s t test. Continuous
data with a skewed distribution are expressed as medians
with IQR, compared using the ManneWhitney U test.
Categorical data are described as numbers and percentages
and analysed using the chi-square test or Fisher’s exact test
as appropriate. The trapezoidal rule was used to calculate
the cTnTeAUC values for each patient profile from the
concentrations of cTnT during the first 30 days after
surgery. To facilitate the analyses with cTnTeAUC, cTnT
levels were divided into tertiles (AUC1; 0.29 days*ng ml1
(0.13e0.33), AUC2; 0.89 days*ng ml1 (0.62e1.56) andAUC3; 8.67 days*ng ml1 (5.99e23.12)). The levels of cTnT
within the normal range were used as reference and an
AUC1eAUC3 represents those with an increasing
cTnTeAUC. Gender, cardiac risk factors (prior history of MI,
CHF, stroke, angina, renal dysfunction, diabetes and age)
and type and site of surgery were entered during the
multivariable analysis. Estimates of the C-statistic for the
Cox regression models were calculated and covariate-
adjusted receiver operating characteristic (ROC) plots were
generated for models both with and without cTnT. The
increased discriminative value of the cTnTeAUC level was
examined to establish the change in the predictive survival
probabilities for cardiovascular events and all-cause
mortality (cTnTeAUC ROC). The relationship between
cTnTeAUC and long-term cardiovascular events and all-
cause mortality were assessed with Cox proportional
hazards models. In addition, a cumulative 1-year survival
curve for vascular surgery patients with and without
cTnT release was determined by the KaplaneMeier method
and compared using the log-rank test. Hazard ratios (HRs)
are given with 95% confidence intervals (CIs). For all tests,
a p-value of less than 0.05 (two-sided) was considered
significant. All analyses were performed using Statistical
Package for Social Sciences (SPSS) 15.0 statistical software
(SPSS Inc., Chicago, IL, USA).
Results
The baseline clinical characteristics of the 513 included
patients are listed in Table 1. The mean age at baseline
was 69  10 years and 77% were male. The preoperative
cardiac risk was assessed and showed that 17% of the
patients had a low risk, 56% an intermediate risk and 27%
a high risk.
Perioperative outcome
During the first 30 days after surgery, 20/513 (4%) patients
died of which 19/20 (95%) deaths were due to cardiovascular
causes. As many as 13 of the 20 patients with perioperative
death experienced perioperative cTnT release. During the
first 30 days after surgery, abnormal cTnT levels were
detected in 81/513 (16%) patients of which 54 (67%) also had
postoperative ECG changes. A total of eight patients were
classified as having an STEMI (10%) and 46 (57%) as non-STEMI
(Table 2). Only 6/81(7%) patients had typical chest pain
complaints. The median cTnT level was 0.11 ng ml1 (IQR
0.06e0.64). An elevated cTnT level was detected in 38% of
patients undergoing an open abdominal aortic aneurysm
(AAA) repair, in 7% of those undergoing endovascular AAA
repair, in 17% of the lower extremity revascularisation group
and in 2% of those undergoing carotid endarterectomy. A
total of seven patients underwent coronary artery revascu-
larisation during the perioperative period. The median
cTnTeAUCwas 0.89 days*ngml1 (IQR 0.33e6.02). As shown
in Table 1, patients in the highest cTnTeAUC tertile were
significantly older, more often had a history of MI, CHF and
renal dysfunction and more often underwent high-risk
vascular surgery procedures. Patients with an STEMI were
more often situated in the highest cTnTeAUC (p < 0.001,
Table 2) tertile.
Table 1 Baseline characteristics and cTnTeAUC.
All
n Z 513
No cTnT
n Z 432
AUC1
n Z 27
AUC2
n Z 27
AUC3
n Z 27
p-Value
Age, years 68.9  9.5 68.5  9.6 68.7  10.1 72.5  7.6 72.6  7.3 0.04
Males e no. (%) 397 (77) 327 (76) 22 (82) 23 (85) 25 (93) 0.14
History of MI e no. (%) 143 (28) 107 (25) 10 (37) 13 (48) 13 (48) 0.003
History of angina pectoris e no. (%) 87 (17) 70 (16) 5 (19) 5 (19) 7 (26) 0.61
History of CHF e no. (%) 39 (8) 27 (6) 1 (4) 5 (19) 6 (22) 0.002
Diabetes mellitus e no. (%) 109 (21) 87 (20) 7 (26) 8 (30) 7 (26) 0.54
Renal dysfunction e no. (%) 39 (8) 21 (5) 2 (7) 7 (26) 9 (33) <0.001
History of stroke e no. (%) 192 (37) 167 (39) 7 (26) 9 (33) 9 (33) 0.53
Hypertension e no. (%) 262 (51) 217 (50) 13 (48) 15 (56) 17 (63) 0.58
COPD e no. (%) 185 (36) 144 (33) 9 (33) 17 (63) 15 (56) 0.002
Smoking e no. (%) 393 (77) 332 (77) 21 (78) 18 (67) 22 (82) 0.60
Preoperative cardiac risk 0.001
Low risk (no risk factors) 89 (17) 83 (19) 3 (11) 1 (4) 2 (7)
Intermediate risk (1 or 2 risk
factors)
288 (56) 247 (57) 18 (67) 12 (44) 11 (41)
High risk (3 risk factors) 136 (27) 102 (24) 6 (22) 14 (52) 14 (52)
Medication
Beta-blockers e no. (%) 468 (91) 389 (90) 26 (96) 26 (96) 27 (100) 0.17
Statins e no. (%) 430 (84) 357 (83) 24 (89) 26 (96) 23 (85) 0.25
anti-platelet therapy e no. (%) 388 (76) 323 (75) 25 (93) 19 (70) 21 (78) 0.18
Oral anticoagulants e no. (%) 72 (14) 62 (14) 2 (7) 5 (19) 3 (11) 0.65
Angiotensin converting enzyme
inhibitors e no. (%)
147 (29) 122 (28) 8 (30) 7 (26) 10 (37) 0.78
Diuretics e no. (%) 122 (24) 97 (23) 4 (15) 12 (44) 9 (33) 0.03
Site and type of surgery <0.001
Open AAA repair e no. (%) 131 (26) 81 (19) 13 (48) 18 (67) 19 (70)
Endovascular AAA repair e no. (%) 123 (24) 114 (26) 3 (11) 3 (11) 3 (11)
Lower extremity artery
bypasse no. (%)
111 (22) 92 (21) 9 (33) 5 (19) 5 (19)
Carotid endarterectomy e no. (%) 100 (19) 97 (23) 2 (7) 1 (4) 0 (0)
Carotid artery stenting e no. (%) 48 (9) 48 (11) 0 (0) 0 (0) 0 (0)
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During a median follow-up of 2 years (IQR 1.1e3.1), 87
(17%) patients died. Table 2 shows that patients with higher
cTnT levels had a significantly higher incidence of mortality
as compared with patients without cTnT release (32/81
(40%) vs. 55/432 (13%); p < 0.001) and cardiovascular
events (54/81 (67%) vs. 43/432 (10%); p < 0.001). Cardio-
vascular events and long-term mortality occurred more
often in those in the highest cTnTeAUC tertile as comparedTable 2 Events and cTnTeAUC.
All
n Z 513
No cTnT
n Z 432
STEMI e no. (%) 8 (2) 0 (0)
Non-STEMI e no. (%) 46 (9) 0 (0)
Cardiovascular eventsa e no. (%) 97 (19) 43 (10)
All-cause mortality e no. (%) 87 (17) 55 (13)
a Cardiovascular events were defined as non-fatal MI, unstable angi
vascular cause, including deaths following a cardiac procedure, card
ascribed to other causes).with those in the lowest or intermediate cTnTeAUC ter-
tiles. In univariate analysis, an increased cTnTeAUC was
associated with an increased risk of long-term cardiovas-
cular events and all-cause mortality (Fig. 1, log-rank
p-value < 0.001). The additional value of cTnTeAUC for
predicting the combined end point of cardiovascular events
and all-cause mortality on top of gender, cardiac risk
factors and type and site of surgery, as compared with
those without cTnT release, is portrayed in Fig. 2. As shown
in Tables 3 and 4, those in the highest cTnTeAUC tertileAUC1
n Z 27
AUC2
n Z 27
AUC3
n Z 27
p-Value
0 (0) 2 (7) 6 (22) <0.001
12 (44) 17 (63) 17 (63) <0.001
15 (56) 16 (59) 23 (85) <0.001
7 (26) 10 (37) 15 (56) <0.001
na and cardiovascular death (defined as any death with a cardio-
iac arrest, MI, pulmonary embolus, stroke or sudden death not
Figure 1 An increased cTnTeAUC was associated with an increased risk of all-cause mortality.
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outcome and long-term mortality (HR 20.2; 95% CI
10.2e40.0 and HR 4.0; 95% CI 2.0e7.8, respectively). When
using cTnTeAUC as a continuous variable in multivariate
analyses, this was still found to be a significant predictor of
late cardiovascular events and all-cause mortality (HR 1.07;
95% CI 1.05e1.09 and HR 1.02; 95% CI 1.00e1.04, respec-
tively). C-statistic analyses showed that the best cut-off
value for cTnTeAUC was <0.01 days*ng ml1 for predicting
long-term cardiovascular events and all-cause mortality.
Patients with a cTnTeAUC 0.01 days*ng ml1 had signif-
icantly more events during the long-term follow-up. A sub
analysis with the addition of postoperative ECG changes
and clinical symptoms to the model did not improve the
prediction of either cardiovascular events (cTnTeAUC
C-statistic 0.82; cTnTeAUC, ECG changes and chest pain
C-statistic 0.82, respectively) or all-cause mortality
(C-statistic 0.73 and 0.73, respectively).Figure 2 Multivariate analyses show that increasing cTnTeAUC is
and long-term all-cause mortality.Discussion
This study shows that perioperative cTnT levels
>0.01 days*ngmle1, as well as gradual increasing circulating
levels of cTnT, presented as the cTnTeAUC, have a graded
relationship with the incidence of cardiovascular events and
all-cause mortality on long-term follow-up of such vascular
surgery patients.
With the use of conventional assays of troponin, the
prevalence of detectable concentrations of cTnT in the
general population is approximately 0.7%.12 Approximately
7% of cTnT exists freely in the cardiac myocyte cytoplasm13
and has an increased precision at the lower end of the
reference range. The mechanisms responsible for the
release of very low levels of cTnT in patients with stable
coronary artery disease (CAD) could include transient,
clinically silent ischaemic episodes and small-vessel occlu-
sions, inflammatory processes, cardiomyocyte apoptosis,associated with an increased risk of cardiovascular (CV) events
Table 3 Uni -and multivariate analyses for the predictive value of gender, cardiac risk factors, site and type of surgery, and
cTnT release on cardiovascular outcome.
Univariate HR (95% CI) Multivariate HR (95% CI)
Gender 1.16 (0.67e1.99) 0.74 (0.44e1.24)
Prior history of MI 2.25 (1.42e3.57) 1.13 (0.72e1.78)
Prior history of CHF 2.99 (1.50e5.94) 1.43 (0.77e2.63)
Prior history of stroke 0.83 (0.52e1.33) 1.78 (1.09e2.92)
Angina 1.58 (0.92e2.73) 1.26 (0.75e2.10)
Renal dysfunction 2.99 (1.50e5.94) 0.93 (0.50e1.72)
Diabetes 0.95 (0.55e1.65) 0.64 (0.38e1.09)
Age 1.03 (1.01e1.06) 1.03 (1.01e1.06)
Site and type of surgery
Open AAA 1.00 1.00
EVAR 0.28 (0.15e0.52) 0.82 (0.42e1.58)
Lower extremity artery bypass 0.51 (0.29e0.91) 1.19 (0.69e2.04)
Carotid endarterectomy 0.08 (0.03e0.22) 0.18 (0.06e0.57)
Carotid artery stenting 0.32 (0.13e0.76) 0.82 (0.31e2.20)
cTnT release
No cTnT release 1.00 1.00
AUC 1 11.31 (4.97e25.72) 7.84 (4.09e15.03)
AUC 2 13.16 (5.74e30.17) 7.08 (3.54e14.15)
AUC 3 52.02 (17.19e157.45) 20.15 (10.16e39.96)
744 T.A. Winkel et al.reduced renal clearance and increased myocardial strain
due to pressure or volume overload.14 In the current study,
patients with more cardiac risk factors were prone to
develop perioperative cTnT release and had more events
during the long-term follow-up. By introducing high-sensi-
tivity cTnT (hs-cTnT) assays, a greater number of patients
will be detected and the first question arises whether minor
changes in very low levels still remain strong predictors ofTable 4 Uni -and multivariate analyses for the predictive value
cTnT release on all-cause mortality.
All-cause mortality Univariate
Gender 1.06 (0.61
Prior history of MI 1.65 (1.02
Prior history of CHF 2.36 (1.15
Prior history of stroke 0.51 (0.30
Angina 1.02 (0.56
Renal dysfunction 2.70 (1.33
Diabetes 0.54 (0.28
Age 1.04 (1.01
Site and type of surgery
Open AAA 1.00
EVAR 0.49 (0.27
Lower extremity artery bypass 0.46 (0.24
Carotid endarterectomy 0.07 (0.02
Carotid artery stenting 0.34 (0.13
cTnT release
No cTnT release 1.00
AUC 1 2.40 (0.97
AUC 2 4.03 (1.76
AUC 3 8.57 (3.81events than do conventional and/or absolute levels and,
second, whether serial testing of cTnT would enhance the
prognostic value of the assay. In a study by Omland et al.,
3679 patients with stable CAD were followed for a median
time of 5.2 years and it was concluded that also hs-cTnT
concentrations were significantly associated with the inci-
dence of cardiac death and heart failure.15 In the current
study, this was also the case for the lowest cTnTeAUCof gender, cardiac risk factors, site and type of surgery, and
HR (95% CI) Multivariate HR (95% CI)
e1.84) 0.76 (0.45e1.31)
e2.69) 1.09 (0.68e1.76)
e4.87) 1.57 (0.81e3.05)
e0.86) 0.69 (0.38e1.26)
e1.89) 0.86 (0.48e1.54)
e5.50) 1.68 (0.88e3.18)
e1.04) 0.56 (0.30e1.04)
e1.07) 1.04 (1.02e1.07)
1.00
e0.89) 0.69 (0.38e1.26)
e0.86) 0.79 (0.44e1.40)
e0.24) 0.19 (0.05e0.68)
e0.86) 0.88 (0.30e2.55)
1.00
e5.94) 1.89 (0.83e4.31)
e9.25) 2.04 (0.97e4.33)
e19.26) 3.96 (2.01e7.78)
Troponin T Quantification and Long-term Outcome 745(AUC1) tertile being associated with an eight-fold increased
risk of cardiovascular events as compared with those
without cTnT release. Furthermore, the current analyses
showed that the detection of cTnT in low levels indicates
a higher detection of cardiovascular events and all-cause
mortality on the long-term outcome.
In a study by Miller et al., serial cTnT samples were
collected in 172 patients with CHF (New York Heart
Association class IIIeIV).16 They concluded that elevations
in cTnT, even when using a low threshold of
0.01 ng mle1, were highly associated with an increased
risk of events, particularly with frequent or persistent
cTnT elevations of 0.01 ng mle1.16 We sought to elab-
orate on the hypothesis that an increased cTnTeAUC
emerging from serial measurements of cTnT would
provide incremental risk stratification information in
addition to gender, cardiac risk factors and type and site
of surgery in predicting adverse cardiovascular events and
mortality. These findings might lead to an understanding
of what types and timing of intervention might be
effective in the management of these at-risk patients. In
patients with chest pain complaints suspected for acute
coronary syndrome, early detection using ECG could offer
the opportunity of timely thrombolysis. In a study of 3027
patients, of whom 362 were randomised to pre-hospital
vs. hospital thrombolysis, a significant resolution of
ST-segment elevation was achieved due to timely inter-
vention.17 This setting is significantly different from the
immediate postoperative period in which patients are
recovering from surgery, where systemic thrombolysis is
commonly not feasible. In addition, the vast majority of
patients are asymptomatic, stressing the importance of
objective detection of myocardial damage. The optimal
intervention in patients with immediate postoperative ST-
segment changes has not been clarified yet. The early
warning by standard assessment of cTnT levels in the
perioperative period with short time intervals, for
example, on days 1, 2 and 3, postoperatively, and ECG
abnormalities offers the opportunity to stratify the
patient to intensified therapy. Despite multiple studies
assessing the significance of perioperative MI measured by
ECG monitoring,18e20 the study by Muehlschlegel et al.
showed that none of the ECG criteria for myocardial
injury predicted mortality; however, cTnT levels inde-
pendently predicted 5-year mortality.21 Similar results
have been found in the current analyses, in which this is
also the case, being that there is no additional predictive
value of postoperative ECG changes and clinical symp-
toms on top of increasing cTnTeAUC. Importantly,
however, as is also shown in the current study, post-
operative ischaemia is silent in the majority of cases,
making it difficult to detect.19 Landesberg and colleagues
found that long duration (>2 h) of silent subendocardial
ischaemia, using continuous 12-lead ECG, is predictive of
postoperative cardiac complications.22,23 Patients who
developed an MI had more than five-fold longer episodes
of ischaemia, and the cumulative ischaemia duration was
greater than seven-fold, compared with patients with
ischaemia but no MI.22,23 This indicates that timely
intervention might improve postoperative outcome.Limitations
Potential limitations of the current study merit consider-
ation. First, is there an optimal cut-off value of cTnTeAUC
and hs-cTnT that could aid clinicians in distinguishing
patients at most risk of cardiovascular events and
mortality? With the current study findings, one could say
that the mere presence of a cTnTeAUC is associated with
an increased incidence of long-term cardiovascular events.
Second, in the majority of cases, continuous ECG recordings
were stopped by the time cTnT release occurred. Contin-
uous ECG monitoring for a longer period of time may
increase the potential detection of myocardial ischaemia in
those patients with perioperative ECG changes, which
could ensure that asymptomatic and paroxysmal cases are
not missed. Third, cTnT measurements were not done in
a continuous online fashion, but were performed at fixed
times or when clinical symptoms indicated myocardial
damage. Finally, although medication at discharge was
recorded, no data on medication during the follow-up
period were available.
In conclusion, the present study shows that, in vascular
surgery patients, an increased cTnTeAUC strongly predicts
late mortality and cardiovascular events. Furthermore,
patients with an increased perioperative cTnTeAUC should
be highlighted, investigated and treated aggressively in an
attempt to reduce late cardiovascular events or death after
vascular surgery.
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